45 pending office actions • 14 clients
| Client (Assignee) | Pending OAs |
|---|---|
| AstraZeneca AB | 11 |
| AstraZeneca AB | 10 |
| MedImmune, LLC | 7 |
| MedImmune, LLC | 5 |
| MedImmune, LLC | 2 |
| AstraZeneca AB | 2 |
| Ionis Pharmaceuticals, Inc. | 1 |
| Cincor Pharma, Inc. | 1 |
| USYNOVA PHARMACEUTICALS LTD. | 1 |
| AstraZeneca AB | 1 |
| Ionis Pharmceuticals, Inc. | 1 |
| MedImmune, LLC | 1 |
| Mitsubishi Tanabe Pharma Corporation | 1 |
| DANA-FARBER CANCER INSTITUTE, INC. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18719343 | COMPOSITIONS, METHODS AND SYSTEMS FOR AEROSOL DRUG DELIVERY | AstraZeneca AB | HAGHIGHATIAN, MINA | 1616 | Non-Final OA | Jun 13, 2024 |
| 18698811 | PEPTIDE DENDRONS AND METHODS OF USE THEREOF | AstraZeneca AB | ESPINOSA, CLAUDIA EDILMA | 1654 | Non-Final OA | Apr 05, 2024 |
| 18693356 | METHODS OF TREATING INFLAMMATORY DISEASES WITH A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR | AstraZeneca AB | OTTON, ALICIA L | 1699 | Non-Final OA | Mar 19, 2024 |
| 18585339 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Ionis Pharmaceuticals, Inc. | BEANE, RANDALL L | 1654 | Final Rejection | Feb 23, 2024 |
| 18443829 | SPIROCYCLIC COMPOUNDS | AstraZeneca AB | HABTE, KAHSAY | 1624 | Non-Final OA | Feb 16, 2024 |
| 18421142 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS | AstraZeneca AB | STAVROU, CONSTANTINA E | 1632 | Non-Final OA | Jan 24, 2024 |
| 18414885 | COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN THE TREATMENT OF NRAS MUTATED CANCER | AstraZeneca AB | MCKOY, QUINCY ANDRE | 1626 | Non-Final OA | Jan 17, 2024 |
| 18539471 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Dec 14, 2023 |
| 18569853 | METHODS OF USING ALDOSTERONE SYNTHASE INHIBITORS | Cincor Pharma, Inc. | RODRIGUEZ, RAYNA B | 1628 | Non-Final OA | Dec 13, 2023 |
| 18564778 | METHODS OF TREATING BREAST CANCER | AstraZeneca AB | FETTEROLF, BRANDON J | 1626 | Non-Final OA | Nov 28, 2023 |
| 18492216 | METHODS OF TREATMENT OF BREAST CANCER | AstraZeneca AB | SCHMIDT, IZABELA MARIA | 1621 | Non-Final OA | Oct 23, 2023 |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | MedImmune, LLC | CHATTIN, AMY MARIE | 1643 | Non-Final OA | Oct 05, 2023 |
| 18552300 | COMBINATION TREATMENT FOR MELANOMA | AstraZeneca AB | HADDAD, MAHER M | 1641 | Non-Final OA | Sep 25, 2023 |
| 18552014 | FORMULATION COMPRISING CERALASERTIB | AstraZeneca AB | LEE, SIN J | 1613 | Final Rejection | Sep 22, 2023 |
| 18470548 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB | JACKSON, SHAWQUIA | 1626 | Non-Final OA | Sep 20, 2023 |
| 18550548 | CONTROL OF MULTI-GENE EXPRESSION USING SYNTHETIC PROMOTERS | AstraZeneca AB | SMITH, ADAM MICHAEL | 1638 | Non-Final OA | Sep 14, 2023 |
| 18550546 | SYSTEM AND METHOD FOR ONLINE DETECTION OF A POST-TRANSLATIONAL MODIFICATION OF A POLYPEPTIDE | AstraZeneca AB | BERKE-SCHLESSEL, DAVID W | 1651 | Non-Final OA | Sep 14, 2023 |
| 18467137 | THERAPEUTIC BINDING MOLECULES | MedImmune, LLC | SKOKO III, JOHN JOSEPH | 1643 | Final Rejection | Sep 14, 2023 |
| 18276334 | PYRIMIDINE AROMATIC RING COMPOUNDS | USYNOVA PHARMACEUTICALS LTD. | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | Aug 08, 2023 |
| 18001637 | DETERGENT AND METHOD FOR PURIFYING A BIOTHERAPEUTIC | MedImmune, LLC | SWIFT, CANDICE LEE | 1657 | Final Rejection | Jul 14, 2023 |
| 18346884 | IL33 ANTIBODIES AND METHODS OF USING THE SAME | MedImmune, LLC | BUCCINI, MICHELLE CALLAHAN | 1675 | Non-Final OA | Jul 05, 2023 |
| 18256484 | METHODS OF PRODUCING ADENOVIRUS | AstraZeneca AB | GRIZER, CASSANDRA SENN | 1672 | Non-Final OA | Jun 08, 2023 |
| 18319560 | AMIDO HETEROAROMATIC COMPOUNDS | AstraZeneca AB | MAHLUM, JONATHAN DAVIS | 1625 | Non-Final OA | May 18, 2023 |
| 18252818 | PHARMACEUTICAL FORMULATION | AstraZeneca AB | PUTTLITZ, KARL J | 1646 | Non-Final OA | May 12, 2023 |
| 18247014 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB | TOWNSLEY, SARA ELIZABETH | 1629 | Non-Final OA | Mar 28, 2023 |
| 18246206 | TREATMENT METHODS USING ANTI-CD73 AND ANTI-PD-L1 ANTIBODIES AND CHEMOTHERAPY | MedImmune, LLC | XIAO, YAN | 1642 | Non-Final OA | Mar 22, 2023 |
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | Ionis Pharmceuticals, Inc. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | Non-Final OA | Mar 16, 2023 |
| 18245422 | OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS | AstraZeneca AB | HILL, KEVIN KAI | 1638 | Non-Final OA | Mar 15, 2023 |
| 18177387 | OPTIMIZED RATIOS OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH CONCENTRATIONS OF PROTEIN-BASED THERAPEUTIC AGENTS | MedImmune, LLC | BRADLEY, CHRISTINA | 1654 | Final Rejection | Mar 02, 2023 |
| 18172449 | COMPOUNDS AND THEIR USE | Mitsubishi Tanabe Pharma Corporation | LEE, WILLIAM Y | 1623 | Non-Final OA | Feb 22, 2023 |
| 18169497 | COMBINATION THERAPIES FOR TREATMENT OF CANCER WITH THERAPEUTIC BINDING MOLECULES | MedImmune, LLC | BUNNER, BRIDGET E | 1647 | Final Rejection | Feb 15, 2023 |
| 18006054 | SARS-COV-2 PROTEINS, ANTI-SARS-COV-2 ANTIBODIES, AND METHODS OF USING THE SAME | AstraZeneca AB | BERHANE, SELAM | 1675 | Non-Final OA | Jan 19, 2023 |
| 18056367 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | AstraZeneca AB | PYLA, EVELYN Y | 1633 | Non-Final OA | Nov 17, 2022 |
| 17998388 | FORMULATIONS OF ANTI-IL-33 ANTIBODIES | MedImmune, LLC | BELYAVSKYI, MICHAIL A | 1644 | Final Rejection | Nov 10, 2022 |
| 17998275 | ATR INHIBITORS FOR THE TREATMENT OF CANCER | AstraZeneca AB | HIRAKIS, SOPHIA P | 1623 | Non-Final OA | Nov 09, 2022 |
| 17997376 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICALLY ACTIVE AGENTS | MedImmune, LLC | ESPINOSA, CLAUDIA EDILMA | 1654 | Non-Final OA | Oct 28, 2022 |
| 17917333 | COMPOSITIONS AND METHODS FOR IMPROVED SITE-SPECIFIC MODIFICATION | AstraZeneca AB | ALLEN, SARAH ELIZABETH | 1637 | Non-Final OA | Oct 06, 2022 |
| 17907683 | STABILIZED IGG4 ANTIBODIES AND USES THEREOF | MedImmune, LLC | BRISTOL, LYNN ANNE | 1643 | Final Rejection | Sep 29, 2022 |
| 17906123 | THERAPEUTIC METHODS FOR THE TREATMENT OF SUBJECTS WITH RISK ALELLES IN IL33 | MedImmune, LLC | KAPUSHOC, STEPHEN THOMAS | 1683 | Non-Final OA | Sep 12, 2022 |
| 17759388 | ANTI-avB8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE | MedImmune, LLC | HADDAD, MAHER M | 1641 | Non-Final OA | Jul 25, 2022 |
| 17755605 | METHODS OF USING IL-33 ANTAGONISTS | MedImmune, LLC | MERTZ, PREMA MARIA | 1674 | Final Rejection | May 03, 2022 |
| 17755604 | ANTI IL-33 THERAPEUTIC AGENT FOR TREATING RENAL DISORDERS | MedImmune, LLC | BERHANE, SELAM | 1675 | Final Rejection | May 03, 2022 |
| 17772187 | DRY POWDER FORMULATIONS CONTAINING LEUCINE AND TRILEUCINE | AstraZeneca AB | HAGHIGHATIAN, MINA | 1616 | Non-Final OA | Apr 27, 2022 |
| 17595671 | COMBINATION THERAPY | DANA-FARBER CANCER INSTITUTE, INC. | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Nov 22, 2021 |
| 17599374 | COMPOUNDS AND CONJUGATES THEREOF | MedImmune, LLC | GAUGER, PAUL RANDALL | 1629 | Final Rejection | Sep 28, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial